HLA associations in classical Hodgkin lymphoma: EBV status matters

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Huang, Xin ^a,b   Kushekhar, Kushi ^a   Nolte, Ilja ^a   Kooistra, Wierd ^a   Visser, Lydia ^a   Bouwman, Ilby ^a   Kouprie, Niels ^a   Veenstra, Rianne ^a   van Imhoff, Gustaaf ^a   Olver, Bianca ^c   Houlston, Richard S ^c   Poppema, Sibrand ^a   Diepstra, Arjan ^a   Hepkema, Bouke ^a   van den Berg, Anke ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HLA A1 ANTIGEN; HLA A2 ANTIGEN; HLA ANTIGEN; HLA B37 ANTIGEN; HLA B5 ANTIGEN; HLA B7 ANTIGEN; HLA CW6 ANTIGEN; HLA DR10 ANTIGEN; HLA DR2 ANTIGEN; HLA DR5 ANTIGEN; HLA DR7 ANTIGEN; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CASE CONTROL STUDY; CLASSICAL HODGKIN LYMPHOMA; CONTROLLED STUDY; EPSTEIN BARR VIRUS; FEMALE; GENE; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENOTYPE; HAPLOTYPE; HLA GENE; HLA TYPING; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPHOCYTE-RICH CLASSICAL HODGKIN LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MIXED CELLULARITY HODGKIN LYMPHOMA; NETHERLANDS; NODULAR SCLEROSIS HODGKIN LYMPHOMA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALLELES; CASE-CONTROL STUDIES; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENE FREQUENCY; HAPLOTYPES; HERPESVIRUS 4, HUMAN; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HODGKIN DISEASE; HUMANS; INFECTIOUS MONONUCLEOSIS; LINKAGE DISEQUILIBRIUM; MALE; MIDDLE AGED;

HUMAN HERPESVIRUS 4;

EID: 84863668616     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0039986     Document Type: Article

References (36)

1. Landgren O, Caporaso NE, (2009) New aspects in descriptive, etiologic, and molecular epidemiology of Hodgkin's lymphoma. Hematol Oncol Clin North Am 21: 825-840.
2. Kuppers R, (2009) The biology of Hodgkin's lymphoma. Nat Rev Cancer 9: 15-27.
3. Sonmez M, Erkut N, Ucar F, Buruk K, Cobanoglu U, et al. (2010) Familial Hodgkin's lymphoma from the perspective of HLA. Intern Med 49: 607-610.
4. Cartwright RA, Watkins G, (2004) Epidemiology of Hodgkin's disease: a review. Hematol Oncol 22: 11-26.
5. Diepstra A, Niens M, Vellenga E, van Imhoff GW, Nolte IM, et al. (2005) Association with HLA class I in Epstein-Barr-virus-positive and with HLA class III in Epstein-Barr-virus-negative Hodgkin's lymphoma. Lancet 365: 2216-2224.
6. Diepstra A, Niens M, Te Meerman GJ, Poppema S, van den Berg A, (2005) Genetic susceptibility to Hodgkin's lymphoma associated with the human leukocyte antigen region. Eur J Haematol pp. 34-41.
7. Harty LC, Lin AY, Goldstein AM, Jaffe ES, Carrington M, et al. (2002) HLA-DR, HLA-DQ, and TAP genes in familial Hodgkin disease. Blood 99(2): 690-693.
8. Depil S, Morales O, Auriault C, (2004) Hodgkin's disease and Epstein-Barr virus. Ann Biol Clin (Paris) 62: 639-648.
9. Lee SP, Tierney RJ, Thomas WA, Brooks JM, Rickinson AB, (1997) Conserved CTL epitopes within EBV latent membrane protein 2: a potential target for CTL-based tumor therapy. J Immunol 158: 3325-3334.
10. Voo KS, Fu T, Wang HY, Tellam J, Heslop HE, et al. (2004) Evidence for the presentation of major histocompatibility complex class I-restricted Epstein-Barr virus nuclear antigen 1 peptides to CD8+ T lymphocytes. J Exp Med 199: 459-470.
11. Kruger S, Schroers R, Rooney CM, Gahn B, Chen SY, (2003) Identification of a naturally processed HLA-DR-restricted T-helper epitope in Epstein-Barr virus nuclear antigen type 1. J Immunother 26: 212-221.
12. Marshall WH, Barnard JM, Buehler SK, Crumley J, Larsen B, (1997) HLA in familial Hodgkin's disease. Results and a new hypothesis. Int J Cancer 19: 450-455.
13. Hansen JA, Young CW, Whitsett C, Case DC Jr, Jersild C, et al. (1977) HLA and MLC typing in patients with Hodgkin's disease. Prog Clin Biol Res 16: 217-227.
14. Hafez MM, el-Wehedy GF, el-Kholy NM, el-Shawaf IM, Mahmoud ME, et al. (1985) The value of HLA phenotypes in the prognosis of Hodgkin's lymphoma. Int J Cancer 36: 19-22.
15. Niens M, van den Berg A, Diepstra A, Nolte IM, van der Steege G, et al. (2006) The human leukocyte antigen class I region is associated with EBV-positive Hodgkin's lymphoma: HLA-A and HLA complex group 9 are putative candidate genes. Cancer Epidemiol Biomarkers Prev 15: 2280-2284.
16. Niens M, Jarrett RF, Hepkema B, Nolte IM, Diepstra A, et al. (2007) HLA-A*02 is associated with a reduced risk and HLA-A*01 with an increased risk of developing EBV+ Hodgkin lymphoma. Blood 110: 3310-3315.
17. Hjalgrim H, Rostgaard K, Johnson PC, Lake A, Shield L, et al. (2010) HLA-A alleles and infectious mononucleosis suggest a critical role for cytotoxic T-cell response in EBV-related Hodgkin lymphoma. Proc Natl Acad Sci U S A 107: 6400-6405.
18. Enciso-Mora V, Broderick P, Ma Y, Jarrett RF, Hjalgrim H, et al. (2010) A genome-wide association study of Hodgkin Lymphoma identifies new susceptibility loci at 2p16.1 (REL), 8q24.21, and 10p14 (GATA3). Nature Genetics 42(12): 1126-1130.
19. Urayama KY, Jarrett RF, Hjalgrim H, Diepstra A, Kamatani Y, et al. (2012) Genome-wide association study of classical Hodgkin lymphoma and Epstein-Barr virus status-defined subgroups. J Natl Cancer Inst 104(3): 240-253.
20. Helmberg W, Lanzer G, Zahn R, Weinmayr B, Wagner T, et al. (1998) Virtual DNA analysis - a new tool for combination and standardised evaluation of SSO, SSP and sequencing-based typing results. Tissue Antigens 51: 587-592.
21. Bjorkman PJ, Parham P, (1990) Structure, function, and diversity of class I major histocompatibility complex molecules. Annu Rev Biochem 59: 253-288.
22. Cano P, Klitz W, Mack SJ, Maiers M, Marsh SG, et al. (2007) Common and well-documented HLA alleles: report of the Ad-Hoc committee of the american society for histocompatiblity and immunogenetics. Hum.Immunol 68: 392-417.
23. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, et al. (2007) PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 81: 559-575.
24. Stephens M, Scheet P, (2005) Accounting for decay of linkage disequilibrium in haplotype inference and missing data imputation. Am J Hum Genet 76: 449-462.
25. Stephens M, Smith NJ, Donnelly P, (2001) A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 68: 978-989.
26. Schipper RF, Schreuder GMT, D'Amoro J, Oudshoorn (1996) HLA gene and haplotype frequencies in Dutch blood donors. Tissue Antigens 48: 562-574.
27. Ghodke Y, Joshi K, Chopra A, Patwardhan B, (2005) HLA and disease. Eur J Epidemiol 20: 475-488.
28. Huang X, Hepkema B, Nolte I, Kushekhar K, Jongsma T, et al. (2012) HLA-A*02:07 is a protective allele for EBV negative and a susceptibility allele for EBV positive classical Hodgkin lymphoma in China. PLoS One 7(2): e31865.
29. Marescotti D, Destro F, Baldisserotto A, Marastoni M, Coppotelli G, et al. (2010) Characterization of an human leucocyte antigen A2-restricted Epstein-Barr virus nuclear antigen-1-derived cytotoxic T-lymphocyte epitope. Immunology 129(3): 386-395.
30. Bell MJ, Abbott RJ, Croft NP, Hislop AD, Burrows SR, (2009) An HLA-A2-restricted T-cell epitope mapped to the BNLF2a immune evasion protein of Epstein-Barr virus that inhibits TAP. J Virol 83(6): 2783-2788.
31. Rickinson AB, Moss DJ, (1997) Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection. Annu Rev Immunol 15: 405-431.
32. Hildesheim A, Apple RJ, Chen CJ, Wang SS, Cheng YJ, et al. (2002) Association of HLA class I and II alleles and extended haplotypes with nasopharyngeal carcinoma in Taiwan. J Natl Cancer Inst 94: 1780-1789.
33. Burt RD, Vaughan TL, McKnight B, Davis S, Beckmann AM, et al. (1996) Associations between human leukocyte antigen type and nasopharyngeal carcinoma in Caucasians in the United States. Cancer Epidemiol Biomarkers Prev 5: 879-887.
34. Murray RJ, Wang D, Young LS, Wang F, Rowe M, et al. (1988) Epstein-Barr virus-specific cytotoxic T-cell recognition of transfectants expressing the virus-coded latent membrane protein LMP. J Virol 62: 3747-3755.
35. Hors J, Dausset J, (1983) HLA and susceptibility to Hodgkin's disease. Immunol Rev 70: 167-92.
36. Robertson SJ, Lowman JT, Grufferman S, Kostyu D, van der Horst CM, et al. (1987) Familial Hodgkin's disease. A clinical and laboratory investigation. Cancer 59: 1314-1319.